However, secukinumab, an antibody against IL-17A, is only approved for the treatment of psoriasis arthritis and ankylosing spondylitis while IL-17A neutralisation in RA had less convincing clinical effects so far15. Here, IL17A is linked to rheumatoid arthritis.